FDA’s Pazdur Calls Accelerated Approval An “Interim Decision” With Ariad In Mind
This article was originally published in RPM Report
Executive Summary
Three days before Ariad ceded to FDA’s request to suspend marketing of its lung cancer drug Iclusig, the agency’s top cancer drug reviewer discussed how he views the accelerated approval process.